China Urology Devices Market Overview,2030

The urology devices market in China has rapidly evolved alongside the country’s expanding healthcare modernization and rising burden of urinary and kidney-related diseases. With more than 260 million people aged over 60 according to China’s National Bureau of Statistics, the demand for urological interventions for benign prostatic hyperplasia, kidney stones, and bladder cancer has surged, making China one of the largest consumers of urological equipment in Asia. Over the past decade, the transition from open to minimally invasive and robotic-assisted surgery has redefined urological care, particularly in tertiary hospitals such as Peking Union Medical College Hospital, Ruijin Hospital in Shanghai, and West China Hospital in Chengdu. The introduction of flexible endoscopy, fiber-optic cystoscopes, and laser-based lithotripsy systems has improved procedural precision and reduced hospitalization time. China’s academic research centers, including Tsinghua University and Zhejiang University, are actively developing AI-enabled imaging tools and 3D-printed surgical models for preoperative planning. Tele-urology has also gained traction through digital health platforms like Ping An Good Doctor and WeDoctor, allowing specialists to provide consultations and postoperative monitoring remotely. Home-use urology devices, including portable bladder scanners and catheters, have seen growing adoption among patients with mobility challenges and chronic renal disorders. Domestic innovation is supported by government initiatives such as “Healthy China 2030,” which emphasizes preventive care, infection control, and use of disposable and eco-friendly medical tools. Robotics in urology has been accelerated by the approval of systems like the Toumai robot, developed by Chinese company Tinavi Medical Technologies, which competes with international robotic platforms. The National Medical Products Administration (NMPA) oversees safety certifications aligned with ISO and CE standards, while stringent sterilization and reprocessing policies are enforced across public hospitals. The integration of smart sensors, wearable urinary monitoring systems, and real-time data analytics is steadily transforming China’s urology landscape into a technologically advanced and patient-focused medical ecosystem.

According to the research report, ""China Urology Devices Market Overview, 2030,"" published by Bonafide Research, the China Urology Devices market is anticipated to add to more than USD 2.13 Billion by 2025–30. China’s urology devices market is defined by strong domestic manufacturing capabilities, international collaborations, and growing adoption of robotic and laser-based systems in both urban and regional hospitals. Leading hospitals such as Zhongshan Hospital in Shanghai and the First Affiliated Hospital of Sun Yat-sen University have expanded outpatient urology units equipped with state-of-the-art endoscopic and lithotripsy devices to perform same-day procedures, reflecting the country’s shift toward minimally invasive and day-care surgery. Major international manufacturers, including Olympus, Karl Storz, and Boston Scientific, maintain extensive operations in China through local subsidiaries and distributors such as Sinopharm and United Imaging Healthcare. Domestic companies like Mindray Medical, Lepu Medical, and MicroPort Scientific have diversified their product lines to include endoscopic imaging systems, catheters, and dialysis equipment tailored for the Chinese healthcare market. Strategic partnerships, such as the collaboration between Intuitive Surgical and Fosun Pharma, have localized robotic production and service support, significantly reducing equipment costs for hospitals. The National Health Security Administration’s reimbursement programs cover most urological procedures, improving accessibility for middle-income patients. AI-driven diagnostic software, co-developed by Huawei Cloud and the Chinese Academy of Sciences, is being implemented in hospitals to enhance detection of prostate abnormalities and urinary tract obstructions. The Ministry of Industry and Information Technology has introduced regulatory incentives for domestic startups working on biodegradable stents and nano-coated materials that improve patient safety. Investment activity in digital urology technology is increasing, with healthcare venture funds like Hillhouse Capital and Sequoia China financing AI-enabled monitoring platforms. Local supply chains ensure cold chain logistics and sterile packaging compliance, while firms such as Shanghai Medical Device Service Center manage device calibration and maintenance.

In China, the urology devices market by type is shaped by the country’s rapid healthcare modernization, increasing prevalence of urological diseases, and strong local manufacturing base supported by international collaborations. The product category includes advanced diagnostic and therapeutic instruments such as endoscopes, cystoscopes, ureteroscopes, laser and lithotripsy systems, and dialysis machines used widely in top medical institutions like Peking Union Medical College Hospital in Beijing, Ruijin Hospital in Shanghai, and West China Hospital in Chengdu. Flexible and rigid endoscopes from manufacturers such as Olympus, Karl Storz, and Mindray are extensively used for endoscopic surgeries and diagnostic procedures. Laser and lithotripsy devices employing Holmium:YAG and Thulium fiber technologies are integral to the treatment of urinary stones and prostate enlargement, with local production from companies such as Lumenis China and Wuxi Huarui Laser Technology contributing to cost efficiency. Extracorporeal shock wave lithotripsy units are standard in urology departments across provincial hospitals, reflecting their popularity for non-invasive stone management. Dialysis devices supplied by Fresenius, Baxter, and domestic firms like Weigao and Nikkiso China are essential in managing kidney failure, especially in urban centers facing high chronic kidney disease prevalence. The accessories segment encompasses a wide range of consumables including Foley catheters, ureteral stents, drainage bags, lubricating gels, and guidewires essential for daily clinical operations. Chinese companies such as Lepu Medical and Kindly Medical Instruments manufacture high-quality catheters and stents that meet international standards. Lubricants and sterile gels are used routinely in urological examinations and catheterizations to ensure patient comfort and procedural safety. Infection control initiatives from the National Health Commission have encouraged the widespread use of disposable and single-use accessories across hospitals. This integration of high-end equipment with reliable local consumable production underlines China’s capacity to deliver modern, efficient, and patient-oriented urological care across its extensive healthcare system.

In China, urology devices are used across a broad spectrum of clinical applications that mirror the country’s demographic shifts, technological advances, and public health priorities. Urolithiasis (stone disease) is one of the most common urological conditions, particularly prevalent in southern regions like Guangdong and Guangxi, where high temperatures and mineralized water contribute to stone formation. Hospitals such as Zhongshan Hospital in Shanghai and Guangdong Provincial People’s Hospital use flexible ureteroscopes, nephroscopes, and laser lithotripters to treat complex kidney stones through minimally invasive procedures. Benign Prostatic Hyperplasia (BPH) is treated with laser vaporization systems, transurethral resection tools, and water vapor therapy devices at major centers like Tongji Hospital in Wuhan. Urological cancers, including prostate, bladder, and kidney cancers, are treated using robotic-assisted surgical systems such as the da Vinci Surgical System and Chinese-developed robots like MicroHand in cancer hospitals such as Fudan University Cancer Center. Urinary incontinence and pelvic organ prolapse management is expanding in women’s hospitals like Peking University First Hospital, where slings, artificial sphincters, and bulking agents are commonly used. Erectile dysfunction is treated in andrology clinics across Beijing and Shanghai using penile implants, vacuum erection systems, and regenerative medicine-based therapies. Kidney diseases are a growing concern in China due to rising diabetes and hypertension rates, leading to increased use of dialysis machines and urine management systems in nephrology-urology departments. Other applications include pediatric urology procedures in hospitals like Beijing Children’s Hospital, where specialized miniature endoscopes and soft catheters are used for congenital conditions, strictures, and infections. Chinese healthcare providers emphasize precision, infection control, and minimally invasive approaches, supported by government initiatives to expand advanced urological services beyond tier-one cities, reflecting a nationwide commitment to improving clinical outcomes in both urban and rural regions.

In China, urology devices are utilized across hospitals, clinics, dialysis centers, and home care settings that together form a multi-layered healthcare delivery system. Hospitals and clinics are the dominant end users, with top-tier institutions such as Peking Union Medical College Hospital, West China Hospital, and Ruijin Hospital leading in the adoption of robotic surgery, endoscopic systems, and laser lithotripters for complex urological procedures. Public hospitals under the National Health Commission are equipped with advanced diagnostic suites featuring digital cystoscopes, ureteroscopes, and laser treatment units, while private clinics in cities like Shanghai, Shenzhen, and Guangzhou increasingly offer outpatient cystoscopy, lithotripsy, and prostate therapy services using compact and portable devices. Medical universities, including Sun Yat-sen University, play a central role in surgical training and research on next-generation urology technologies. Dialysis centers across China have expanded rapidly in response to the rising burden of chronic kidney disease, with major operators such as Fresenius Medical Care China, Weigao, and Diaverum managing facilities in Beijing, Tianjin, and Chengdu. These centers utilize hemodialysis and peritoneal dialysis equipment integrated with urology monitoring systems to manage patients with overlapping renal and urinary tract conditions. Collaboration between nephrology and urology specialists ensures comprehensive treatment continuity. Home care settings have gained prominence as government healthcare reforms encourage chronic disease management outside hospitals. Home-use devices such as intermittent catheterization kits, portable drainage systems, and compact dialysis machines are increasingly available through local health programs in provinces like Jiangsu and Zhejiang. Companies such as Coloplast China and B. Braun provide education and training programs to help patients safely manage urological conditions at home.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Urology Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Product
• Accessories

By Application
• Urolithiasis (Stone Disease)
• Benign Prostatic Hyperplasia (BPH)
• Urological Cancers
• Urinary Incontinence & Pelvic Organ Prolapse
• Erectile Dysfunction
• Kidney Diseases
• Other Applications (Pediatrics, Strictures, Infections, etc.)

By End Use
• Hospitals and clinics
• Dialysis centers
• Others (Home care settings) Show more